Skip to main content
Premium Trial:

Request an Annual Quote

Labcorp OmniSeq Insight

Laboratory Corporation of America and OmniSeq have launched the OmniSeq Insight genomic and immune profiling test. The tissue-based test integrates next-generation sequencing technology to advance precision oncology, the firms said. OmniSeq Insight is a pan-cancer solid tumor test for genomic and immune profiling, including tumor mutational burden, microsatellite instability, and immune gene expression. Results are presented in an easy-to-read report that provides recommendations specific to the patient's results based on a proprietary database that includes information and guidelines from the National Comprehensive Cancer Network. The test is available to US clinicians exclusively through Labcorp and in Canada through Dynacare, a Labcorp company.

Labcorp and OmniSeq, a molecular diagnostics subsidiary of Roswell Park Cancer Institute, signed a distribution agreement in 2017 for OmniSeq's immune profiling and pan-cancer NGS tests, and they extended the deal in 2019.

The Scan

Billion-Dollar Diversity Initiative

The Howard Hughes Medical Institute is now accepting applications for its new $1.5 billion initiative to boost the diversity of the scientific workforce.

Biotech Co-Founder Arrested

A co-founder of a Los Angeles-based biotech company has been arrested in connection with a murder-for-hire scheme, according to Endpoint News.

Return of the Tasmanian Tiger

The Washington Post reports that a team in Australia is working to bring the thylacine back from extinction.

Nature Papers on Genome of Individual From Pompeii, CircRNA Study Best Practices, More

In Nature this week: first sequenced genome of a person from Pompeii, best practice guidelines for circRNA studies, and more.